FAAH Pharma, Inc.

FAAH Pharma, is a biotech company, focus on the development of vaccination and drug for the treatment of postherpetic neuralgia and pain. Its lead candidate is IPI-940 , developed in collaboration with Infinity Pharmaceuticals Inc.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.faahpharma.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1255 University, # 1610,Quebec H3B 3X3
Montreal
Canada
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Aug 2014, Infinity Pharmaceuticals Inc. granted FAAH Pharma, an exclusive, worldwide rights to develop IPI-940 to treat neuralgia and pain disease.

In Aug 2014, FAAH Pharma, announced an investment by TVM Life Science Ventures VII into the company, for clinical development of a compound with the potential to treat neuropathic pain.